INSP vs VMD
INSP: Inspire Medical Systems manufactures implantable nerve stimulation devices that treat obstructive sleep apnea without surgery or continuous positive airway pressure (CPAP). VMD: Viemed provides home-based respiratory, chronic care, and women's health services with clinical practitioners delivering therapy and equipment rental to patients across all 50 US states.
Side-by-side fundamentals
| Metric | INSP | VMD | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $50.40 | $11.92 | |
| Market cap as of 2026-07-23 | $1.5B | $456M | |
| P/E as of 2026-07-23 | 11.06 | 30.61 | INSP lower |
| PEG as of 2026-07-23 | 0.11 | 0.93 | INSP lower |
| Net margin as of 2026-07-23 | +14.3% | +5.2% | INSP higher |
| Gross margin as of 2026-07-23 | +85.8% | +57.6% | INSP higher |
| Operating margin as of 2026-07-23 | +5.2% | +8.2% | VMD higher |
| ROE as of 2026-07-23 | +18.0% | +10.7% | INSP higher |
| ROA as of 2026-07-23 | +15.3% | +7.6% | INSP higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.06 | INSP lower |
| Revenue growth (YoY) as of 2026-07-23 | +8.9% | +23.1% | VMD higher |
| Revenue CAGR (3y) SEC XBRL | +30.8% | +24.9% | INSP higher |
| Beta as of 2026-07-23 | 0.66 | 1.12 | |
| 1-year return as of 2026-07-22 close | -61.1% | +83.4% | VMD higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.